Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Gianpietro Dotti
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bluebird Bio
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The SFIs of the investigator are related to the funded research since the technology being used in the project has been licensed to the company with which the investigator has multiple relationships. The Institution has determined that since the technology could be further validated as a result of the research, these financial interests could conflict with project.
Safety and anti-tumor activity of B7-H3 CAR T cells in TNBC
Narrative The long range goal of this program is to develop and implement an effective therapy for metastatic triple negative breast cancer (TNBC). In our strategy T cells genetically engineered with tumor antigen-specific chimeric antigen receptor s (CAR) have been selected as the effector mechanism. B7-H3 has been selected as the target. A B7-H3-specific CAR has been generated from our mAb 376.96. In preliminary studies we have found that B7-H3-specific CAR T cells are effective in eliminating TNBC cells in vitro. However they also target dendritic cells therefore raising questions about the toxicity of B7-H3-specific CAR T cell-based immunotherapy. This proposal will test the safety and anti-tumor activity of B7-H3-specific CAR T cells both in an immunocompetent and in an immunodeficient host. The resulting information will contribute to determine the clinical potential of B7-H3-specific CAR T cell- based immunotherapy for the treatment of TNBC.
Filed on May 07, 2019.
Tell us what you know about Gianpietro Dotti's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Gianpietro Dotti filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Gianpietro Dotti | Massachusetts General Hospital | Conflict of Interest | Bluebird Bio | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.